By a News Reporter-Staff News Editor at Drug Week -- Current study results on Doxorubicin have been published. According to news originating from Mashhad, Iran, by NewsRx correspondents, research stated, "Every year a large number of new cases of colorectal cancer are diagnosed in the world. Application of Epirubicin (Epi) in treatment of cancer has been limited due to its cardiotoxicity."
Our news journalists obtained a quote from the research from the Mashhad University of Medical Sciences, "Specific delivery of chemotherapy drugs is an important factor in reducing the side effects of drugs used in chemotherapy. Enhanced permeability, retention effect and magnetic resonance (MR) traceability of super paramagnetic iron oxide nanoparticles (SPION) make them a great candidate in cancer therapy and imaging. In this study, Epirubicin-5TR1 aptamer-SPION tertiary complex was evaluated for the imaging and treatment of murine colon carcinoma cells (C26 cells, target). For cytotoxic studies (MTT assay), C26 and CHO-K1 (Chinese hamster ovary cells, nontarget) cells were treated with either Epi or Epi-Apt-SPION tertiary complex. Internalization was evaluated by flow cytometry. Finally, Apt-SPION bioconjugate was used for imaging of cancer in vivo. Flow cytometric analysis showed that the tertiary complex was internalized effectively to C26 cells, but not to CHO-K1 cells. Cytotoxicity of Epi-Apt-SPION tertiary complex also confirmed internalization data. The complex was less cytotoxic in CHO-K1 cells when compared to Epi alone. No significant change in viability between Epi- and complex-treated C26 cells was observed. Magnetic resonance imaging (MRI) indicated a high level of accumulation of the nano-magnets within the tumor site."
According to the news editors, the research concluded: "Epi-Apt-SPION tertiary complex is introduced as an effective system for targeted delivery of Epi to C26 cells. Moreover this complex could efficiently detect tumors when analyzed by MRI and inhibit tumor growth in vivo."
For more information on this research see: Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo. European Journal of Pharmaceutical Sciences, 2013;50(2):191-197. European Journal of Pharmaceutical Sciences can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; European Journal of Pharmaceutical Sciences - www.elsevier.com/wps/product/cws_home/523997)
The news correspondents report that additional information may be obtained from S.H. Jalalian, Mashhad Univ Med Sci, Sch Pharm, Pharmaceut Res Center, Mashhad, Iran. Additional authors for this research include S.M. Taghdisi, N.S. Hamedani, S.A.M. Kalat, P. Lavaee, M. ZandKarimi, N. Ghows, M.R. Jaafari, S. Naghibi, N.M. Danesh, M. Ramezani and K. Abnous (see also Doxorubicin).
Keywords for this news article include: Iran, Asia, Mashhad, Therapy, Treatment, Epirubicin, Doxorubicin, Naphthacenes, Anthracyclines
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC